BPC-157 + TB-500
In stockOne lyophilized vial supplying BPC-157 and TB-500 (synthetic thymosin beta 4) together. Each component is also listed on its own page with its chemistry and cited studies.
Supplied as a co-lyophilized vial with a colour-coded cap (Recovery & Repair).
Research literature, not dosing or treatment instructions.
- BPC-157 + TB-500: Compared BPC-157, synthetic thymosin beta 4 (TB-500) and their combination in a rat Achilles tendon model with biomechanical and histological analyses. (PMID 42542926)
- BPC-157: In cultured rat tendon cells BPC 157 was examined for effects on tendon outgrowth, cell survival and cell migration. (PMID 21030672)
- TB-500: Thymosin beta 4 is described as the main G-actin sequestering peptide in mammalian tissue and as a mediator of cell migration, proliferation and differentiation. (PMID 14500546)
Add the solvent slowly along the vial wall; swirl gently, never shake. Allow to dissolve fully. Six-step guide with photos →
Concentration calculator only. Enter the mass being calculated; blend components are not added automatically. Products are for in-vitro research.
Refer to the product label and supplier documentation for storage conditions. Lot-specific storage and expiry information is not available here.
Each certificate is published with its lot number.
Questions about BPC-157 + TB-500
Is BPC-157 + TB-500 an approved medicine?
BPC-157 + TB-500 combines research compounds we also list on their own. It is not a medicinal product, and it is supplied for in-vitro laboratory research only, not for human or veterinary use. Regulator records are listed per component on the pages of BPC-157 and TB-500.
Which two compounds are in this vial?
BPC-157, a synthetic 15-residue peptide, and TB-500, the name used for synthetic thymosin beta 4, a 43-residue peptide. They are listed separately as single compounds.
Is there published research on BPC-157 + TB-500 as a combination?
No formulation-level literature is listed. One 2026 rat study compared BPC-157, synthetic thymosin beta 4 and their combination in an Achilles tendon model. (PMID 42542926) The page of each component in the research library lists its own studies.
Is this product for human use?
No. Peptency products are supplied for in-vitro research only. Not for human or veterinary use, not for diagnosis or therapy.
Where can I find shipping information?
Current shipping rates and delivery information are on the Shipping & payment page, and the rates that apply to your order are shown at checkout.
Often studied with
For research use only. Not for human or veterinary use.
What is BPC-157 + TB-500?
A catalog item that supplies BPC-157 and TB-500 (synthetic thymosin beta 4) together in one vial from the same lot. Each component keeps its own chemistry, cited studies and regulator records, listed below. We supply BPC-157 + TB-500 as a lyophilized vial for in-vitro laboratory research only.
What does a BPC-157 + TB-500 vial contain?
BPC-157 + TB-500 supplies BPC-157 and TB-500 together in one vial. The single compounds are listed separately; the amount of each in the vial is shown on the product options.
What does published research on BPC-157 + TB-500 cover?
BPC-157 + TB-500 combines compounds we also list on their own, so no study covers this exact vial beyond the one noted below. Each component has its own studies, checked in PubMed on 5 October 2026. One cited study per component follows.
- BPC-157 + TB-500: Compared BPC-157, synthetic thymosin beta 4 (TB-500) and their combination in a rat Achilles tendon model with biomechanical and histological analyses. (Biçer et al., Jt Dis Relat Surg, 2026; PMID 42542926)
- BPC-157: In cultured rat tendon cells BPC 157 was examined for effects on tendon outgrowth, cell survival and cell migration. (Chang et al., J Appl Physiol (1985), 2011; PMID 21030672)
- TB-500: Thymosin beta 4 is described as the main G-actin sequestering peptide in mammalian tissue and as a mediator of cell migration, proliferation and differentiation. (Philp et al., FASEB J, 2003; PMID 14500546)
Mechanism, every cited study and the regulator records are on the BPC-157 + TB-500 page of the research library. Papers are listed by what they measured, not as evidence of any use.
How is BPC-157 + TB-500 supplied and stored?
BPC-157 + TB-500 is supplied as a co-lyophilized (freeze-dried) powder in a sealed vial, for in-vitro laboratory research only. Our stated storage condition for the sealed lyophilized vial is 2 to 8 °C. The label and the lot certificate carry the lot-specific storage condition and expiry date.
What is the regulatory status of BPC-157 + TB-500?
BPC-157 + TB-500 combines research compounds we also list on their own. It is not a medicinal product. Regulator records are listed per component.
BPC-157: The EMA medicines database (checked 5 October 2026) lists no centrally authorised medicine naming BPC-157 (searched as BPC) as an active substance. National authorisations are not in that dataset.
TB-500: The EMA medicines database (checked 5 October 2026) lists no centrally authorised medicine naming TB-500 (searched as thymosin beta or timbetasin) as an active substance. National authorisations are not in that dataset.
A regulator record is information about a database entry. It is not advice and not a statement that any use is lawful or unlawful in any country. How regulators approach research peptides.
Which related research pages and compounds are listed?
Components in the catalog: